Patient perspective on watchful waiting/active surveillance for localized prostate cancer
- PMID: 23136314
- PMCID: PMC4212643
- DOI: 10.3122/jabfm.2012.06.120128
Patient perspective on watchful waiting/active surveillance for localized prostate cancer
Abstract
Objective: To describe prostate cancer treatment decision making, focusing on knowledge and attitudes toward observation, known as watchful waiting (WW) or active surveillance (AS), and reasons for not choosing WW/AS.
Methods: Semistructured in-person interviews were conducted with 21 men (14 black; 7 white) with recently diagnosed localized prostate cancer.
Results: All cancers were detected by prostate-specific antigen screening; 14 men had low-risk disease. Nineteen chose surgery or radiation treatment. The majority wanted to "get rid of" or "cure" the cancer by undergoing aggressive therapy, even with awareness of the potential for significant side effects. Most men seemed unaware of the uncertainty/controversies that aggressive treatment may not cure their cancer or improve their survival. Limited knowledge about WW/AS was common, and few remembered WW/AS being presented as a viable option. Rather, many men perceived it as "doing nothing." Some men, who initially were inclined toward WW/AS, yielded to pressure from family, physicians, or both to choose aggressive treatment. Lack of physician support was a significant barrier to WW/AS.
Conclusions: The observational strategy (WW/AS) was not viewed as a reasonable approach, even for those with low-risk cancer. The desire for aggressive therapy may reflect the complex psychology associated with receiving a diagnosis of cancer and the limited supportive counseling received. Further efforts to better understand and educate patients and physicians may help men make informed and appropriate treatment decisions to maximize quality of life without compromising survival.
Conflict of interest statement
Similar articles
-
Racial Differences in Treatment Decision-Making for Men with Clinically Localized Prostate Cancer: a Population-Based Study.J Racial Ethn Health Disparities. 2016 Mar;3(1):35-45. doi: 10.1007/s40615-015-0109-8. Epub 2015 May 5. J Racial Ethn Health Disparities. 2016. PMID: 26896103 Free PMC article.
-
Men's perspectives on selecting their prostate cancer treatment.J Natl Med Assoc. 2011 Jun;103(6):468-78. doi: 10.1016/s0027-9684(15)30359-x. J Natl Med Assoc. 2011. PMID: 21830629 Free PMC article.
-
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.Eur Urol. 2017 Dec;72(6):899-907. doi: 10.1016/j.eururo.2017.07.018. Epub 2017 Aug 23. Eur Urol. 2017. PMID: 28844371 Free PMC article.
-
Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.Semin Urol Oncol. 2002 Feb;20(1):10-7. doi: 10.1053/suro.2002.30393. Semin Urol Oncol. 2002. PMID: 11828353 Review.
-
Radical prostatectomy versus watchful waiting for prostate cancer.Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006590. doi: 10.1002/14651858.CD006590.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2020 Jun 4;6:CD006590. doi: 10.1002/14651858.CD006590.pub3. PMID: 21069689 Updated. Review.
Cited by
-
Exploring the potential of single-metals (Cu, Ni, Zn) decorated Al12N12 nanostructures as sensors for flutamide anticancer drug.Heliyon. 2023 Oct 11;9(10):e20682. doi: 10.1016/j.heliyon.2023.e20682. eCollection 2023 Oct. Heliyon. 2023. PMID: 37867907 Free PMC article.
-
A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.BMC Cancer. 2023 Apr 10;23(1):327. doi: 10.1186/s12885-023-10747-z. BMC Cancer. 2023. PMID: 37038138 Free PMC article.
-
Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.Prostate. 2023 May;83(6):498-515. doi: 10.1002/pros.24493. Epub 2023 Feb 22. Prostate. 2023. PMID: 36811453 Free PMC article. Review.
-
Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancer.Cancer Med. 2023 Mar;12(5):6307-6317. doi: 10.1002/cam4.5405. Epub 2022 Nov 20. Cancer Med. 2023. PMID: 36404625 Free PMC article.
-
Risk of progression following a negative biopsy in prostate cancer active surveillance.Prostate Cancer Prostatic Dis. 2023 Jun;26(2):403-409. doi: 10.1038/s41391-022-00582-x. Epub 2022 Aug 25. Prostate Cancer Prostatic Dis. 2023. PMID: 36008540 Free PMC article.
References
-
- Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605–13. - PubMed
-
- Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics. PSA doubling times, and outcome. Eur Urol. 2007;51:1244–51. - PubMed
-
- Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868–78. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials